Drug delivery platform for the local biological therapy of ocular inflammation
Bidragets beskrivning
Inflammation of the eye (also called uveitis) affects young adults aged 20-50 (sometimes also children) and can lead to blindness. Biological therapeutics are very effective in the treatment of ocular inflammation, however they must be administered systemically and can cause serious side-effects, including cancer. This project aims to develop a novel treatment that allows the safe and effective delivery of biological therapeutics directly to the eye. This local delivery is achieved by using short pieces of RNA called aptamers that can target the biological therapeutics to the inflammation site inside the eye.The method used to find these aptamers is called SELEX. Aptamer-targeted biological therapeutics are also embedded inside hydrogels, this allows their prolonged release and thus decreases the administration frequency. Overall, this project will develop a safer and more comfortable treatment for patients with ocular inflammation and thus decrease their risk of getting blind.
Visa merStartår
2020
Slutår
2026
Beviljade finansiering
Andra beslut
336280
Akademiforskarens forskningskostnader(2020)
231 806 €
Finansiär
Finlands Akademi
Typ av finansiering
Akademiforskare
Utlysning
Övriga uppgifter
Finansieringsbeslutets nummer
333301
Vetenskapsområden
Farmaci
Forskningsområden
Farmasia
Identifierade teman
eyes, eye diseases